A study using clinical samples suggested that the GRB7/extracellular signal-regulated kinases (ERK)/forkhead box M1 (FOXM1) signaling cascade is a promising molecular therapeutic target for ovarian cancer [18]. Here, FOXM1 is linked to ovarian cancer.